The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016

References

• Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol. 1988;27:627–647.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group–DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008;47:497–505.
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Bjerre KD, Christiansen P, et al. Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG registry. Acta Oncol. 2008;47:525–536.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Ejlertsen B, Mouridsen HT, et al. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55(2):24–35.
   Web of Science ®Google Scholar
• Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342:1317–1322.
   PubMed Web of Science ®Google Scholar
• Francke AL, Smit MC, de Veer AJ, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008;8:38.
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen MB, Ejlertsen B, et al. Danish Breast Cancer Cooperative Group. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506–524.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer; 2012.
   Google Scholar
• Kiaer HW, Laenkholm AV, Nielsen BB, et al. Classical pathological variables recorded in the Danish Breast Cancer Cooperative Group’s register 1978–2006. Acta Oncol. 2008;47:778–783.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174–185.
   PubMed Web of Science ®Google Scholar
• Laenkholm AV, Jensen MB, Eriksen JO, et al. The PAM50 risk of recurrence score predicts 10 year distant recurrence in a comprehensive Danish cohort of 2558 postmenopausal women allocated to 5 year of endocrine therapy for hormone receptor positive early breast cancer. J Clin Oncol. 2018;57: in press.
   Google Scholar
• Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219–3232.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis a randomized clinical trial. JAMA. 2011;305:569–575.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007; 2:3846–3852.
   Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795.
   PubMed Web of Science ®Google Scholar
• Laenkholm AV, Grabau D, Talman ML, et al. An inter observer Ki67 reproducibility study applying two different assessment methods. On behalf of the Danish Scientific Committee of Pathology, Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol. 2018; in press.
   PubMed Web of Science ®Google Scholar
• Thorsen LB, Thomsen MS, Overgaard M, et al. Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: the DBCG-IMN study. Acta Oncol. 2013;52:1526–1534.
   PubMed Web of Science ®Google Scholar
• Thorsen LB, Thomsen MS, Berg M, et al. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects. Acta Oncol. 2014;53:1027–1034.
   PubMed Web of Science ®Google Scholar
• Thorsen LB, Offersen BV, Danoe H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314–321.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor–positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103:1363–1372.
   PubMedGoogle Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.
   PubMed Web of Science ®Google Scholar
• BIG 1–98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–131.
   PubMed Web of Science ®Google Scholar
• Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial. J Natl Cancer Inst. 2008;100:121–133.
   PubMed Web of Science ®Google Scholar
• Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106:2337–2344.
   PubMed Web of Science ®Google Scholar
• Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ. 1997;157:408–416.
   PubMed Web of Science ®Google Scholar
• Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation-a scoping review. Healthcare (Basel). 2016;4:36.
   PubMedGoogle Scholar
• Banta D, Kristensen FB, Jonsson E. A history of health technology assessment at the European level. Int J Technol Assess Health Care. 2009;25(1):68–73.
   Web of Science ®Google Scholar
• Nicholson BD, Mant D, Neal RD, et al. International variation in adherence to referral guidelines for suspected cancer: a secondary analysis of survey data. Br J Gen Pract. 2016;66:e106–e113.
   PubMed Web of Science ®Google Scholar
• Austad B, Hetlevik I, Mjølstad BP, et al. Applying clinical guidelines in general practice: a qualitative study of potential complications. BMC Fam Pract. 2016;17:92.
   PubMed Web of Science ®Google Scholar